Digital Medicine Society (DiMe)

❗Did you hear about DATAcc by DiMe’s public launch event, “Transforming Alzheimer’s Disease and Related Dementias Research: New Core Digital Clinical Measures”? 📅 On Thursday, Nov. 14 at 11 a.m. ET, we will unveil our new core measures and the accompanying resources for #Alzheimer’s disease and related dementias (ADRD) to help speed clinical trials, improve patient outcomes, and provide a more inclusive, patient-centered approach to ADRD research. ADRD is one of healthcare's most complex and growing challenges, with 95% of those affected also managing chronic #comorbidities. Over 16 million family members and friends are caregivers, facing immense burdens alongside strained #healthcare systems. Yet, research lacks diversity, particularly among Hispanic and non-white populations, leaving critical gaps in understanding how different communities experience and respond to treatments. Our measures reflect meaningful aspects of health as reported by dementia patients, caregivers, and healthcare providers. Join us to learn how you can incorporate these measures and resources into your work to: ▪️ Standardize digital measures across trials to enable more diverse patient recruitment and deliver faster, cost-effective results ▪️ Capture continuous data to empower clinicians with real-world patient insights, leading to more informed and timely decisions ▪️ Increase trial efficiency, reducing costs and ensuring trials are more representative to meet the specific needs of all communities 🔗 Register now: https://bit.ly/3Ul8LGY In the meantime, watch this video where our partners share why digital measures are key to transforming research and care in ADRD. Cogstate, Altoida, Inc., Merck, Eli Lilly and Company, ki:elements

🤖 As a leader in #AI innovation, you know the transformative potential of your solutions for healthcare. But integrating AI into clinical care settings requires more than cutting-edge #technology—it demands strategic planning, regulatory expertise, and collaboration across the entire healthcare ecosystem. 📔 By joining Google and Digital Medicine Society (DiMe) on The Playbook: Implementing AI in Healthcare project, you’ll be at the forefront of driving industry-wide consensus on AI implementation across clinical settings in a safe, secure, equitable and privacy-conscious way. This project will be your opportunity to: ▪️ Examine the cost/benefit of AI implementation to maximize value for your organization ▪️ Address ethical and operational risks, taking actionable steps to safely integrate AI into your care systems ▪️ Integrate your AI solutions seamlessly across care delivery settings ▪️ Navigate federal, regulatory, and reimbursement complexities ▪️ Build consensus and close knowledge gaps with top policymakers, technologists, healthcare systems, clinicians, and patient groups Join us in shaping the future of AI in healthcare and ensuring that these technologies realize their full potential to improve patient outcomes and drive operational efficiency. 👉 Share your interest here: https://lnkd.in/ergr3hQ9

🚨 New project alert! Children with rare diseases are in a race against time—95% of rare diseases lack approved treatments, and the average time to diagnosis is 4.8 years, with 30% of children passing away before their 5th birthday. This reality must change. DATAcc by DiMe’s newest project will bring industry leaders, advocacy groups, researchers, and developers across medicine, #tech, pharma, and regulatory environments together to develop a core set of digital measures for #pediatric rare disease that will help you to: ▪️ Use digital #endpoints proven to speed drug delivery and reduce risk ▪️ Streamline the development of digital health technologies designed for pediatric patients ▪️ Decentralize trials with high-quality data collection to ensure lifesaving therapies are delivered to children when they need it With the FDA issuing final guidance on digital measures in December 2023 and qualifying the first digital endpoint in May 2024, now is the time to build a unified core digital measures set for pediatric rare disease. Your expertise and insights will be instrumental as we chart a new course and build tools that bring high-impact, digital solutions to pediatric rare disease clinical trials. 💬 Share your interest in joining the project here: https://bit.ly/3NagKmk

📸 We loved connecting at HLTH with so many of the first companies with products that have been awarded the #DiMeSeal! Congratulations to these incredible organizations dedicated to raising the bar for quality and trustworthy digital health software products. 👏 Check out https://bit.ly/4e39jbx to see the full list of products and companies. Are you ready to join them? The DiMe Seal offers Developers an opportunity to differentiate your product in a very crowded market. For health systems, payors, and providers, it helps to minimize the time and resources spent searching for quality and trustworthy digital health software products. Click below to register for our upcoming information sessions to learn more! Providers, health systems, & payors 📅 Tues., Oct. 29 11:00 am - noon ET https://bit.ly/4e2TG3W Developers 📅 Thurs., Oct. 31 11:00 am - noon ET https://bit.ly/3YGPwua Let’s shape the future of digital health, together. 🚀 #DigitalHealth #Innovation #DiMeSeal

📅 Counting down to our next Journal Club on October 30 at 11 a.m. ET! Join us for an engaging discussion featuring the following industry experts: 🗣️ Elena Izmailova (Koneksa) 🗣️ Jessie Bakker (Koneksa) 🗣️ Benjamin Vandendriessche Digital Medicine Society (DiMe) The session will explore the complexity of obtaining regulatory endorsement for sensor-based digital health technology (sDHT) endpoints in the US. With the lack of approved drugs based on sDHT-derived endpoints, our speakers will review two key regulatory pathways available to pharmaceutical study Sponsors: the traditional IND pathway and the drug development tool (DDT) pathway. We’ll cover the benefits, challenges, and regulatory considerations of each route. 📰 Take a look at the paper we’ll be discussing: https://bit.ly/3NCNLaS 🔗 Register now to secure your spot: https://bit.ly/4e0d6X5

📢 NEW resources alert! 📅 Join us on Thursday, Nov. 14 at 11 a.m. ET for the public launch event, “Transforming Alzheimer’s Disease and Related Dementias Research: New Core Digital Clinical Measures,” where DATAcc by DiMe will unveil the new Core Measures of ADRD and accompanying resources! 🧠 Alzheimer's disease and related dementias (ADRD) cases are rising globally, with care costs soaring and the burden of care becoming more complex. Chronic comorbidities affect 95% of individuals with ADRD, and over 16 million family and friends are relied on as caregivers, carrying the emotional and #financial weight. Yet, research continues to lack #diversity, especially in underrepresented populations like Hispanic and non-white communities. This leaves gaps in understanding how different populations experience #ADRD and respond to treatments. DATAcc’s new unified core measures for ADRD are specifically designed to fill critical research gaps, prioritize the needs of patients and caregivers, and enhance understanding of diverse populations' experiences and responses to ADRD treatments. 💡 Join this event to learn about: ▪️ The new core set of ADRD measures reflecting independent meaningful aspects of health within the #dementia community ▪️Free resources you can use to quickly implement the measures into your research and care community ▪️Updates to DATAcc’s Library of Digital Measurement Products, the global, evidence-based resource for selecting digital health technologies (DHTs) to implement the core measures DATAcc’s globally accepted set of core ADRD measures will transform the development of #digital measures in ADRD, preventing siloed efforts that limit progress. By placing the patient voice at the heart of novel treatment development we will fuel progress in addressing the complexity of these diseases. 🚀 Join us and be among the first in the field to access the new resources. Register now! https://bit.ly/3Ul8LGY Eli Lilly and Company, Eisai US, Care Partner, Altoida, Inc., Cogstate, Cumulus Neuroscience, ki:elements

What was your favorite part of #HLTH2024 this year? 🙌 It was an incredible few days! We’re beyond grateful for the opportunity to share, connect, and collaborate with so many inspiring leaders and innovators in digital health. A special shoutout to everyone who joined us at the DiMe Partner Program—it was standing-room only for the SECOND year in a row! The energy and engagement in the room were truly unmatched, and it’s clear that our collective drive to advance digital health is stronger than ever. 🚀 From announcing the #DiMeSeal to the amazing turnout at our DiMe Mixer, this week has been filled with powerful conversations, new partnerships, and groundbreaking ideas that will shape the future of #healthcare. 👏 Thank you to our incredible partners, panelists, and the entire DiMe community for making this year’s HLTH USA one to remember. Advocate Health, Blue Shield of California, Curai Health, Gesund.ai, Google Health, Health Advances, Health AI Partnership, Highmark Health, InterSystems, Oshi Health, PedsMrkt, Stanford University School of Medicine, UPMC Enterprises, Verily, Visana Health, Zest Dermatology, Zivian Health, Outcomes4Me

🤝 We're proud to welcome Digital.Health as a platform partner for the DiMe Seal! Their curated page of DiMe Seal awarded products helps decision-makers instantly identify those that demonstrate performance against a comprehensive framework of standards and best practices in evidence, privacy, and security with equity woven throughout. Visit https://lnkd.in/dsUX8vzd to learn more. ❗ Are you a developer looking to differentiate your product? Visit https://lnkd.in/g5HgWwJN and start your evaluation today! #DigitalHealth #DiMeSeal #HealthcareInnovation #Quality #Trust

The #DiMeSeal is officially live at #HLTH2024! 🚀 We’re proud to introduce this transformative program to the healthcare industry, addressing the critical need for trust and quality in digital health software products. Join us in setting a new benchmark for what “good” looks like in #digitalhealth. 🔗 Learn more about the DiMe Seal here: https://lnkd.in/eQCiwJ-g Couldn’t make it to #HLTH2024? No worries! Join one of our upcoming virtual information sessions to see the DiMe Seal platform in action, learn more about how it can benefit you, participate in a live Q&A. 📅 Tues., Oct. 29, 11am-12pm ET - Health systems, providers, and payors Register here: https://bit.ly/40aO5Fn 📅 Thurs., Oct. 31, 11am-12pm ET- Developers Register here: https://bit.ly/3BSeNIS

A big thanks to the Digital Medicine Society (DiMe) for having us on their HLTH USA panel on digital health innovation and V1C yesterday. It was a standing-room-only crowd! Zivian Health CEO/Co-Founder Rafid Fadul, MD, MBA joined fellow DiMe partners Blue Shield of California, InterSystems, and Curai Health for a thought-provoking discussion on regulatory compliance, interoperability, collaboration across the ecosystem, and more. Check out these live photos from #HLTH2024! #digitalhealth #healthcareinnovation #healthcarecompliance #virtualcare #patientcare #telemedicine #healthcarecollaboration #healthcaretechnology